IRX4204 inhibition of acute GVHD did not abrogate GVL responses. Lethally irradiated B6 recipients were received 10⁷ BALB/c T-cell–depleted BM, with or without B6 C1498ff (3 × 10⁴), with or without 1.5 × 10⁶ BALB/c CD25⁻ T cells. Recipients were treated IP with either vehicle or IRX4204 from day 0 to 56 after transplantation. Survival, weights, and BLI graph are shown. Tumor growth was monitored with BLI on the days indicated. BLI images are shown (n = 5-8 per group). One experiment was performed. **P < .01.